Background: Spontaneous occlusion of the renal arteries or their main branches is an infrequently encountered entity. A few papers in the literature provide efficient information about the diagnosis and treatment of this uncommon disorder. Aim: To draw attention and greater awareness of the clinical suspicion of acute renal vascular events in patients presenting with symptoms of nephrolithiasis. Methods: We reviewed the medical records of 6 patients presented with acute flank pain and hematuria, during the last three years. Three patients were suffering from previously undetected atrial fibrillation, one had a known history of hypertension and the remaining two were in normal health. Plain abdominal films and nephrosonography failed to show any evidence of upper urinary tract calculi or other causes of obstruction in all cases. CT angiography was performed after a mean time of 48 hours (range 24-120). Results: Three patients experienced renal artery embolization (two cases of segmental, one case of complete truncal embolization). One patient had thrombosis of renal artery branch aneurysm. One patient was suspected to suffer from fibromuscular hyperplasia, but denied any further investigation. Subsequent diagnostic evaluation did not reveal the cause of segmental renal artery thrombosis in the sixth patient. All but one patients were treated conservatively by anticoagulation therapy alone and one nephrectomy was needed. No other interventional or surgical procedure was offered due to absence of significant deterioration of renal function and time elapsed from the onset of obstruction. Conclusions: Acute renal artery occlusion must be considered in the differential diagnosis of acute flank pain or hematuria, especially when diagnosis of hydroureteronephrosis cannot be established. University of Palermo, Italy, 4 Hospital of Piacenza, Italy, 5 Hospital of Torino, Italy, 6 Hospital of Reggio Emilia, Italy Background. Patients with clinically suspected deep vein thrombosis (DVT) of the lower extremities are usually investigated with ultrasonography. The evaluation may be limited to the proximal veins (two-point ultrasonography), or encompass the entire deep vein system (whole-leg ultrasonography). The latter approach is deemed to be superior, based on its ability to detect isolated calf-vein thrombosis. However, it requires sophisticated and expensive scanners, and high technical skills. We sought to compare the safety and the cost implications of the two strategies. Methods. Consecutive outpatients with suspected DVT were randomized to two-point or whole-leg ultrasonography. The end-point was the 3-month incidence of symptomatic venous thromboembolism (VTE) occurring in patients with a normal initial diagnostic workup. In addition, we also determined the cost implications of managing 100 patients with either strategy. Results. Symptomatic VTE occurred in 7 of 814 patients (0.9%; 95% CI, 0.3 to 1.8) in the two-point group, and in 9 of 775 (1.2%; 0.5 to 2.2) in the wholeleg group (p=0.69). The two-point strategy saved US $ 2,150 for every 100 symptomatic patients investigated. Conclusions. The two diagnostic strategies proved to be similarly safe, although isolated distal deep-vein thrombosis was neither diagnosed nor treated in patients managed with two-point ultrasonography. These results may help clinicians decide the optimal diagnostic strategy for patients with clinically symptomatic DVT. 
/L)] who were treated with lepirudine. All patients fulfilled the clinical diagnostic criteria of HIT, while H/PF4-antibodies were identified by particle-gel-immunoassay and/or by ELISA. In all cases, heparin was discontinued and patients were treated with 7.5mg FPX SC daily or lepirudine (IV 0.15 mg/Kg/h monitored by aPTT), as soon as the diagnosis of HIT was made. Oral anticoagulation was initiated when PLT count was >150x10 9 /L. Left lower limb amputation because of venous gangrene was required in 1 patient before the beginning of FPX vs 2 in lepirudine group. The development of limb gangrene in both groups may have been a result of delayed recognition of HIT. All patients responded with the PLT count normalizing between 1-9 days after initiation of FPX vs 1-8 days after initiation of lepirudine. 1 and 2 patients respectively died from cause not-related to HIT, although PLT count had returned to normal. No patient experienced a new thromboembolic complication or major bleeding. The 36 surviving patients were treated with long-term oral anticoagulation. Conclusion: Although these data suggest that FPX may be useful in patients with acute HIT, additional controlled clinical studies are required to further evaluate its efficacy and safety in the treatment of HIT. Argatroban is a synthetic; reversible; direct thrombin inhibitor (DTI) used in patients with heparin induced thrombocytopenia (HIT). Argatroban as other DTIs prolong PT, aPTT and ecarin clotting time. Argatroban added in vitro in normal platelet poor plasma (PPP) inhibits tissue factor (TF) triggered thrombin generation (TG) in a concentration dependent manner. We studied the influence of platelets and HIT antibodies on the inhibitory effect of argatroban on TG. Argatroban (0 to 2 ÌM) was added in normal platelet rich plasma (PRP) and PPP, PPP from three consecutive HIT patients (PPP-HIT) and in PRP-HIT prepared by mixing normal PRP with PPP-HIT (v/v) . PRP-HIT and PPP-HIT were containing residual heparin (0,035 and 0,07 anti-IIa IU/ml respectively). Thrombin generation was triggered in the presence of 6 pM TF and assessed with ThrombogramThrombinoscope®. In PPP TG was triggered by adding PPP reagent (ThrombogramThrombinoscope®) . Lag time (LT), time to peak (ttP), peak (P); the endogenous thrombin potential (ETP) and the mean velocity index (MVI) of thrombin generation were measured. The concentrations of argatroban which prolonged 2-fold the LT and the ttP and inhibited 50% (IC50) the P, ETP and MVI were calculated. An artifactual increase of thrombin generation was observed in the presence of low argatroban concentrations (0,1 an 0,2 ÌM) probably due to the interference of alpha2macroglobulin-bound thrombin with the fluorogenic substrate. Argatroban inhibitory activity on TG was the same in normal PPP and PRP. HIT antibodies did not influence the inhibitory activity of argatroban either in PRP or in PPP. The presence of traces of heparin in PPP-HIT amplified the inhibition of TG induced by argatroban (Table 1 ). The present study shows that argatroban inhibits by 50% TG at concentrations ranging from 0,9 ÌM to 1 ÌM. The activity of argatroban is not modified by the presence of platelets or HIT antibodies. In contrast; residual heparin present in plasma from HIT patients amplifies the inhibition of thrombin generation. This finding has to be confirmed in a clinical study since it implicates an increased vigilance during the passage from heparin to argatroban treatment in HIT patients. ÌM PRP normal PPP normal PRP-HIT (0,03 aXa/ml) PPP-HIT (0,07 aXa/ml) Lag-time x2 0,9 0,9 0,9 0,1 ttPeak x2 Objective: identify predictive factors of complications and mortality in HITtreated patients Patients and Methods: case-control study involving defined HIT patients with a relative platelet count decrease of over 40% with or without initial thrombosis and biologically confirmed (functional assay +/-ELISA). A patient presenting a complication 48 hours after the HIT onset (thrombosis, DIC, amputation, haemorrhage, death) is considered as a case. Results: 49 cases and 65 controls were included (mean age 67±14 y; 51% women), from cardiovascular (53%) or orthopaedic (5%) surgery, intensive care unit (6%) or medicine (8%). Mean period for complication occurrence was 7 days: death (n=26); thromboses (n=23); DIC (n=6); amputations (n=4) et haemorrhages (n=8). In univaried analysis, compared to control, cases presented: a) an earlier HIT (7,9±3,5 versus 10,1±7,1 d; p=0,03) b) a lower platelet nadir (53±37 versus 70±37 G/L ; p=0,01), c) a more frequent initial thrombosis (59% versus 32%, p=0,004), d) a later heparin withdrawal related to HIT diagnosis (2,8 versus 1,3 d; p=0,01), e) a delayed substitutive treatment (3,7 versus 1,9 d ; (p=0,001), f) an inadequate dosage of substitutive treatment (44% versus 19% ; p=0,004) . In multivaried analysis, predictive factors leading to a worse HIT evolution are: 1) an initial thrombosis occurrence (OR=3,2 [1,3-8]), 2) a delay superior to 48 h for substitutive treatment initiation with danaparoid (OR=6, 6 [2, (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 3] ), 3) insufficient doses of danaparoid for substitutive treatment (OR=4, 3 [1, (5) (6) (7) (8) (9) (10) (11) (12) Baseline coagulation tests included platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen level, and D-Dimmers. Coagulation disorders were estimated preoperatively in all patients with thromboelastography; specific variables measured included reaction time (R), · angle, K-coefficient, maximal amplitude (MA), and coagulation index (CI).
RESULTS:
The standard laboratory tests of coagulation were normal in all patients except in 2 patients with ovarian cancer and disseminated disease were a moderate increase in PT (INR=1.6) was found. Thromboelastography demonstrated: 1) Normal parameters in all patients with colorectal cancer, 2) hypercoagulopathy (increased mean CI: 4.3) in 23 (92%) ovarian cancer patients, and 3) platelet disorders (decreased MA and · angle) in the 2 patients with ovarian cancer and disseminated malignant disease (table 1) . CONCLUSION: The standard coagulation tests are not competent to reveal the hypercoagulopathy that characterizes the patients with ovarian cancer. Patients with colorectal cancer don't demonstrate coagulation disorders either with the standard laboratory tests or with thromboelastography. Changes in thromboelastography occur before changes in the standard coagulation tests are seen, and can enhance the clinical suspicion of malignancy in patients with ovarian cancer. The method is simple, rapid, sensitive and reliable in the diagnosis of coagulation disorders in ovarian cancer patients. Background. Although international guidelines recommend the long-term administration of low-molecular-weight heparin (LMWH) instead of vitamin K antagonists (VKA) for the secondary prevention of venous thromboembolism (VTE) in patients affected by malignant diseases, there is not unanimous consensus on the implementation of LMWH strategy in all cancer patients. Methods. After adjusting for age, sex, and modality of clinical presentation (primary DVT or primary PE), we determined the risk of recurrent VTE and major bleeding in the first three months of anticoagulation in 12 823 patients (11 365 free from malignancy, 1027 with limited cancer disease, and 431 with distant metastases) who were recruited in the international RIETE registry, had an initial treatment with (LMW)heparin overlapped by VKA (INR, 2.0 to 3.0), and were then followed-up for three months. Results. In comparison to patients free from malignancy the adjusted hazard ratio (HR) of recurrent VTE in the whole group of cancer patients was 3.4 (95% CI, 2.5-4.6), and in cancer patients with and without metastases was 5.2 (3.5-7.9) and 2.7 (1.8 to 3.9), respectively; and the adjusted HR of major bleeding was 1.9 (95% CI, 1.3 to 2.6), 3.8 (2.4 to 6.0) and 1.2 (0.7 to 2.0), respectively. Discussion. While the risk of recurrent VTE during VKA treatment is increased both in cancer patients with advanced and in those with limited disease, the risk of major bleeding in the latter group does not differ from that expected in cancer free patients. The systematic adoption of LMWH therapy in all cancer patients following an episode of VTE should be reconsidered. Background: In the randomized, double-blind FX-140 study in patients undergoing colorectal cancer surgery, nadroparin 2850IU was more effective for reducing symptomatic venous thromboembolism (VTE), but was less effective for reducing asymptomatic distal deep-vein thrombosis than enoxaparin 4000IU [1] . Nadroparin was safer in terms of major bleeding (7.3% versus 11.5%, p=0.012). Aims: We performed a post hoc analysis to determine whether age and creatinine clearance (CrCl) influenced these results. Methods: Patients undergoing elective colorectal adenocarcinoma resection were randomized to receive once daily either enoxaparin 40mg or nadroparin 0.3mL subcutaneously for 9±2 days. The primary efficacy outcome was total VTE up to Day 12. The main safety outcome was major bleeding. Results: 1288 patients (median age: 69, range: 26-97 years) were randomized either to enoxaparin (n=635) or to nadroparin (n=653). Age and CrCl did not influence the respective efficacy of enoxaparin and nadroparin. Concerning major bleeding, nadroparin showed a constant benefit in these two subgroups, notably in patients less than 65 years old (7.1% versus 13.4%) and in patients with normal CrCl (6.2% versus 12.7%). Summary/Conclusion: In patients undergoing colorectal cancer surgery, nadroparin 0.3mL was safer in terms of bleeding risk than enoxaparin 40mg regardless of age and CrCl. References: 1. Simonneau G, et al. J Thromb Haemost 2006; 4:1793- Background: Polycythaemia vera and essential thrombocythaemia are chronic Philadelphia-negative myeloproliferative disorders with an increased risk of arterial and venous thrombosis as well as bleeding. Aim: To quantify the benefit and harm of antiplatelet drugs for long-term primary and secondary prophylaxis of arterial and venous thrombotic events in patients with polycythaemia vera or essential thrombocythaemia. Methods: CENTRAL, MEDLINE and EMBASE databases were searched. All RCTs comparing long term (>6 months) use of an antiplatelet drug versus placebo or no treatment in patients with polycythaemia vera or essential thrombocythaemia, were included. Quantitative analysis of outcome was based on an intention-to-treat principle. The overall treatment effect was estimated by the pooled odds ratio (OR) with 95% confidence interval (CI) using a fixed-effect model (Mantel-Haenszel). Results: Two RCTs were included, for a total of 630 patients with polycythaemia vera with no clear indication or contraindication to aspirin therapy. The use of aspirin, compared with placebo, was associated with lower, not statistically significant, risk of fatal thrombotic events (OR 0.20, 95% CI 0.03 to 1.14), without an increased risk of major bleeding (OR 0.99, 95% CI 0.23 to 4.36) . No studies have been published in patients with essential thrombocythaemia and with other antiplatelet drugs.
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ENOXAPARIN 40MG VERSUS
Conclusions:
The available evidence suggests that the use of aspirin is associated with a not statistically significant reduction in the risk of fatal thrombotic events without an increased risk of major bleeding compared with no treatment in patients polycytaemia vera and with no clear indication or contraindication to aspirin therapy. Background: Once-daily 2.5mg fondaparinux initiated 6 hours postoperatively is approved in the prevention of VTE. Aims: We report a pooled analysis of two trials in which 2.5mg fondaparinux was compared with 40mg enoxaparin in hip surgery [1, 2] . The data were analyzed using endpoints recently recommended by the EMEA [3] . Methods: Two randomized, double-blind trials were conducted in 3946 patients undergoing elective hip replacement or hip fracture surgery. Once-daily 2.5mg fondaparinux started 6 hours postoperatively was compared with once-daily 40mg enoxaparin initiated 12±2 hours preoperatively. The primary efficacy outcome was total VTE (venographic or symptomatic DVT, symptomatic PE, or both). The EMEA-efficacy outcome is a composite of proximal venographic or symptomatic DVT, PE, and all-cause death. Major bleeding was the main safety outcome. Results: Fondaparinux was significantly more effective than, and as safe as, enoxaparin regardless of the outcome definition (Table) . When fondaparinux was initiated ≥6 hours after surgery as recommended, the incidence of major bleeding was 2.6% (30/1134). Summary/Conclusion: In hip surgery patients, 2.5mg fondaparinux starting 6 hours postoperatively showed a major benefit over 40mg enoxaparin started preoperatively, with a VTE risk reduction of 50-70% and a comparable safety profile. Background Limited data are available on the comparative efficacy of low-molecular-weightheparin (LMWH) and unfractionated heparin (UFH) for preventing venous thromboembolism (VTE) in hospitalised medical patients, especially in individual patient subgroups. Aim To compare efficacy and safety outcomes in hospitalised medical patients receiving enoxaparin or UFH, for VTE prophylaxis at day 15 and 1 month. Methods Randomised clinical trials comparing enoxaparin (40mg SC/od) and UFH (5000 IU SC/ bid/tid) for prophylaxis in medical inpatients were identified by systematic literature review, and individual patient data obtained. Duration of study treatment was 7-10 days. Endpoints included total VTE (asymptomatic deep-vein thrombosis, symptomatic VTE, fatal pulmonary embolism), symptomatic VTE, mortality, and major bleeding. Relative risk logarithms were pooled by the inverse of the variance weighting method.
References
Results Individual patient data were analysed from 3600 patients from four studies. Conclusions This meta-analysis suggests that in hospitalized medical patients, enoxaparin efficacy is superior to UFH, without significantly increasing the risk of major bleeding. Benefit-to-risk ratio in different subgroups of patients will be presented at the ICT congress. Purpose: We studied the influence of nadroparin treatment on clot formation and thrombin generation process, in patients undergoing CAS. Methods: Citrated whole blood was obtained from 60 patients undergoing CAS and receiving nadroparin (5750 anti-Xa IU/12hrs), 4hrs after the second injection of nadroparin (LMWH-group) and 20 age and sex matched normal volunteers"(control group). In a subgroup of LMWH-patients (n=20) samples were obtained prior to first injection of LMWH. Minimal Tissue Factortriggered thromboelastography (minTF-TEM Rotem® Thromboelastographe) was performed to all patients included in the study. Anti-factor-Xa activity and minimal TF triggered thrombin generation (CAT Thrombograme®) were performed in platelet poor plasma from 20 of the LMWH-patients. Results:. Nadroparin treatment resulted in significant prolongation of clotting time (CT) and clot formation time (CFT) and significantly reduced "a-angle" with 38% of LMWH-patients having thromboelastographic parameters beyond normal maximum limit (NmaxL). Clot firmness, measured by the Maximal Amplitude (MA) of the thromboelastographic trace was not modified by the LMWH treatment. Prolongation of CFT was significantly correlated to the levels of anti-Xa activity in patients' plasma (p=0.04; r 2 =0.7). Nadroparin treatment resulted in significant prolongation of lag-time and the time to reach maximum thrombin generation (ttPeak) and decrease of the rate of the propagation phase of thrombin generation (p<0.005). Conclusion: Minimal TF triggered whole blood thromboelastography performed at the bed-side and thrombin generation assays are sensitive to the antithrombotic effect of nadroparin in patients undergoing CAS. Nadroparin reduces the rate of clot formation and inhibits the initiation and propagation phase of thrombin generation without affecting clot firmness. These results could explain the favorable benefit/risk profile of treatment with nadroparin and allow the proposal of the use of either min-TF TEM or calibrated thrombine generation assay for laboratory monitoring of LMWH treatment in special groups of patients. In the endovascular era, surgical procedures and less invasive endovascular procedures are mutually complementary and not mutually exclusive. Surgical techniques that facilitate subsequent endovascular procedures like thrombolysis, will ensure longer secondary patency. This is a desirable outcome as life expectancy increases. This paper describes a new surgical approach that exemplifies this concept. A 6 or 7 mm PFTE graft is tunneled subcutaneously and laterally from the femoral artery in the groin to the popliteal artery in the popliteal fossa. The subcutaneous location facilitates subsequent thrombolyis, using the bidirectional catheter technique. This paper describes our experience with thrombolysis in these grafts, and the evolution of our current practice. We have used this approach in 37 patients since 1996. Our first patient operated in May 2006 still has a patent femeropopliteal bypass, with palpable pedal pulses, after two successful thrombolysis. Thrombolysis was successful in 92% of patients in whom it was attempted (12 out of 13 patients). Five patients had successful repeat thrombolysis. Twenty two patients operated prior to December 2002 were available for actual 5 year follow up. The actual primary 5 year patency rate was 33%. With thrombolysis, the actual 5 year secondary patency rate increased to 50%.These results compare very favorably with published data for prosthetic infragenicular femeropopliteal bypass grafts. Surgical techniques that facilitate subsequent endovascular interventions like thrombolysis, have the potential to improve long term results. This paper illustrates the benefits of this new approach.
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INFLUENCE OF LMWH TREATMENT ON CLOT FORMATION AND THROMBIN GENERATION IN PATIENTS UNDERGOING CAROTID ANGIOPLASTY AND STENTING (CAS)
K
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BEMIPARIN FOR SECONDARY PROPHYLAXIS (LONG-TERM TREATMENT) OF VENOUS THROMBOEMBOLISM
Background.
Of out-patients with suspected DVT only 20% have the disease confirmed, and the rest is labelled as "DVT-free", after the initial diagnostic work-up. Even some of these patients maintain symptomatic, little is known about their fate within the following 3 months (only 1-2% of them will eventually suffer a subsequent DVT). In a prospective cohort study we assessed the outcome of symptomatic patients in whom DVT was not initially confirmed. Methods: Consecutive symptomatic outpatients were enrolled after objective DVT exclusion. At baseline we gathered information on patients' symptoms and risk factors for DVT; and sought to establish a likely cause for leg complaints. Patients were then scheduled for a 3-months follow-up visit.
Results: 602 subjects were included (mean age 63, 31% male). Commonest leg complaints were pain (80%), oedema (70%), tension (50%), skin redness (34%); the more frequent risk factors were age >65 (52%), varicose veins (24%), obesity (20%), history of leg trauma/fracture (16%), cancer (9%). A likely explanation for leg symptoms was found in 78%; such as erysipelas (14%), superficial phlebitis (13%), trauma (12%), arthrosis (9%), muscle tear (8%). After 3-months followup, 47% of the patients remained asymptomatic, 46% was improved or stable and 7% worsened. The initial suspect of leg complaints was confirmed in 85% and excluded in 15%. In the latter case a new diagnosis was established in 7% (DVT 1%). The mortality rate was 1.6%, without fatal thromboembolic events.
Conclusions:
In patients "DVT-free" after the initial diagnostic workup, a differential diagnosis may be established on clinical grounds in more than 2/3 of the cases, usually due to local causes. The 3-months prognosis is usually benign, with only <10% with worsening symptoms and a <2% mortality rate.
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VENOUS TROMBOEMBOLISM (VTE) REJECTION, APPLYING HIGH-SENSITIVITY D-DIMER DETERMINATION TO PATIENTS WITH UNLIKELY PROBABILITY, EVALUATED BY IMPLICIT ASSESSMENT:
A University of Napoli, Napoli , Italia Background: A normal value in a low sensitivity D-Dimer test excludes unlikely episodes of VTE, using strict explicit clinical assessments (ei. Wells scores). Aims: Efficiency to use high sensitivity test for D-Dimer measurement to exclude unlikely VTE, assessed by implicit clinical judgement (personal experience). Methods: A non-interventional epidemiological survey for all suspicions of VTE, found in a University Hospital (850 beds) or arriving to emergency department. D-Dimer exclusion ( Bio-Merieux), with a cut-off of 500 ngr/ml, was measured in all patients. Selected non-invasive tests (duplex-Doppler, lung scan, angio-CT) were employed. All patients with normal D-Dimer values were followed for three months, searching for a new VTE episode requiring anticoagulant treatment. Results: In one year, 1446 from 1807 suspected VTE episodes, were classified as unlikely by multiple physicians.
-1095 had increased levels of D-Dimer, with 188 episodes confirmed for VTE.
-351 suspicions had a normal value of D-Dimer. Four episodes of DVT were found in this group, three at diagnosis and one in the follow-up. Three were in anticoagulant treatment, and one presented a relapsed DVT. In this setting, sensitivity of D-Dimer exclusion was 99,5 % ( 95 % CI 98,5 -99,8%) , with a predictive negative value of 99,7 % ( 95 % CI 99,1 -100 %). Conclusions: Use of high sensitivity D-Dimer values to reject VTE is safe whichever unlikeliest of VTE criteria is employed, whenever patients on anticoagulants or with a past history of VTE are excluded. This approach allows saving 24 % of expensive non-invasive diagnostic test. Background.. The pleiotropic effects of the OPG/RANKL/RANK system, such as modulation of cell survival, mineralization and inflammation, sugests a posible role of this system in the progression and destabilization of the atheroclerotic lesions. Osteoprotegerin (OPG) is a soluble member of the TNF receptor superfamily. The activity best characterized for OPG is inhibition of RANKL. OPG can bind to RANKL and prevent interaction of its cognate receptor (RANK). OPG can also interact with TRAIL (TNFrelated apoptosis inducing ligand) showing a comparable affinity to that of TRAIL-R3 and TRAIL-R4. OPG may exert direct biological activities independent of its neutralizing effect towards TRAIL and RANKL. Aim of the study: to evaluate the serum levels of TRAIL, OPG and RANKL in patients with acute myocardial infarction.
Patients and methods:
In 20 patients with acute myocardial infarction (AMI) and 11 controls (healthy volunteers) we measured TRAIL (ELISA), OPG (ELISA), RANKL (ELISA), cTnI (IMMULITE). Value (pg/ml) are expressed as mean ± SEM Results. As compared with controls (103 ± 7.98) serum levels of TRAIL are decreased in the group with AMI (85.57 ± 12.66) with no statistical significance. Serum levels of OPG are increased(134.4 ± 13.5) as compared with controls ( 60.19 ± 5.06) ( p < 0.0002). As compared with controls ( 0.62 ± 0.08) the OPG/TRAIL ratio is significantly elevated (2.1 ± 0.36) (p<0.003). A pozitiv correlation between OPG and age (years) (r = 0.688 p< 0.001) and between the OPG/RANKL ratio and age (years) was found. No correlation with the cTnI was found. Conclusions. In AMI serum levels of OPG was significantly elevated while the serum levels of TRAIL are decreased. It is unclear which of OPG or TRAIL plays a pathogenetic or compensatory role in the induction of vascular dysfunction and atherosclerosis. of thromboprophylaxis has been demonstrated in hospitalised medical patients. However, this population represents a broad spectrum of patients, and more evidence for venous thromboembolism (VTE) and bleeding risk factors in different subgroups of patients is needed. Aim To use an individual patient data meta-analysis 1 to identify predictors of VTE and major bleeding risk in 3600 hospitalised medical patients receiving heparin-based prophylaxis. Methods The meta-analysis incorporated individual patient data from hospitalized medical patients randomised to receive enoxaparin (40mg SC/od) or unfractionated heparin (UFH) (5000IU bid/tid) for VTE prophylaxis.
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PREDICTORS OF VENOUS THROMBOEMBOLISM (VTE) AND BLEEDING RISK IN ACUTELY ILL MEDICAL PATIENTS RECEIVING HEPARIN-BASED PROPHYLAXIS
1 Duration of study treatment was 7-10 days. Demographic and medical characteristic data from these patients were included in a multivariable logistic regression model to identify independent predictors of total VTE (asymptomatic deep-vein thrombosis, symptomatic VTE) and major bleeding at day 15. Analysis was adjusted according to the anticoagulant provided. Results Individual patient data were obtained for 3600 hospitalized medical patients. Median age was 71.0 years (61.0-79.0) and 49.3% were female. Patient medical diagnoses included stroke (56.8%), cancer (11.8%), diabetes (21.9%), and heart failure (23.7%). Reported VTE incidence varied from 1.4%-26.2% in different studies (weighted incidence 3.9% [overall population]); incidence of major bleeding varied from 0.3%-0.9% (weighted incidence 0.6%). Independent predictors of VTE and major bleeding will be presented at ICT 2008. Conclusion These data will be valuable for helping physicians to identify patients at risk for VTE, and those most likely to experience major bleeding, while receiving anticoagulant prophylaxis. 
Department of Vascular Biology and Thrombosis Research, Medical University, Vienna, Austria
Aims: Circulating cell-derived microparticles play a major role in thrombotic diseases. Currently available methods to analyse microparticles are not easy to standardize, need specialized technical equipment or detect only a subpopulation of microparticles. Here a new method for quantification of circulating thrombogenic microparticles is evaluated (Technothrombin ® MP Microparticle and Ceveron ® MFU-500). Methods: The principle of this method is based on the differences in thrombin generation between platelet-poor-plasma (PPP) and microparticle-free-plasma (MPFP) obtained by filtration through a 200nm filter using a filtration device (Ceveron ® MFU-500, Technoclone). PPP was prepared by centrifugation for 15min at 2,500xg. MPFP was generated by filtration (Ceveron® MFU-500; 0.2Ìm low protein binding membrane) or by high speed centrifugation (15,000xg for 30min). PPP and MPFP samples were analysed for thrombin generation using the Technothrombin"TGA method. For calibration, dilutions of purified MP from red blood cells were prepared in MPFP and thrombin generation was measured. Recovery of MP from the filter membrane was performed by rinsing the membrane with an equal volume of standard MPFP. In addition, filtered and non-filtered samples were analyzed in standard coagulation assays (PT, aPTT, Fibrinogen, FVIII-activity, Lupus-assay). Results: Peak thrombin from centrifuged (57nM±8) or filtered samples (79nM±11) was not significantly different (p=0.14) but was significantly lower (p<0.05) than that from PPP (171nM±21) indicating that MP have a significant effect on thrombin generation and that centrifugation and filtration are equally effective in removing microparticles. The analysis of purified MP diluted in MP free plasma showed that the difference in peak thrombin before and after filtration correlated to the number of microparticles and thus a calibration curve could be established. Significant differences between PPP and MPFP were found for aPTT tests only in one of three reagents tested (PPP 36.0sec±3.5, MPFP 38.2sec ±3.4, p<0.05) . The Lupus LCA Index for MPFP (34.8±6) was significantly lower than in PPP (47,4±7; p<0.05). For the other coagulation parameters tested no significant difference was found. Conclusions: All these results show that circulating microparticles are a major determinant for thrombin generation and that thrombogenic microparticles can easily and quantitatively be analyzed from the difference in thrombin generation between PPP and MPFP obtained by filtration through Ceveron®MFU-500. It is shown that microparticles have a significant effect on thrombin generation and on some standard clotting assays. We have shown recently (Hron et al. JAMA 2006) that measuring thrombin generation can identify patients at low risk for recurrent venous thromboembolism and that peak thrombin is a suitable parameter to differentiate low risk from high risk patients. In this study we used the same assay (Technothrombin" TGA) to analyze patients at high risk of atherothrombosis (a swiss study of patients with a history of myocardial infarction). Moreover, we investigated the influence of microparticles on thrombin generation in these patients. Thrombin generation was measured using Technothrombin"TGA. The reagent used contained low levels of phospholipid and 5 pM tissue factor. Platelet poor plasma from 178 patients (n=178, age =55±8 ys, male/female = 157/21) who had a previous myocardial infarction and 79 normal age and sex matched controls. (n=79, age = 55±8 ys, male/female = 70/9) was analyzed. Microparticle-free plasma was generated from PPP plasma by filtration through a membrane (0.2 Ìm pore size) using a standardized filtration device (Ceveron" MFU 500, Technoclone). In the control group the mean value for peak thrombin in platelet poor plasma was 252±7.7 nM (mean±SD). A significantly higher (p< 0,05) peak thrombin was found in the group of patients (355±49 nM) when patients without medication were analyzed. In patients on aspirin (n=109) the peak thrombin was not significantly different from untreated patients (297±10 nM) while in patients on oral anticoagulation (n=34) peak thrombin was significantly lower (225±27 nM). In the group of patients on oral anticoagulation also the lag period was significantly longer as compared to controls or patients without medication (21.9±2 minutes versus 14.8±0.2 minutes) whereas aspirin treatment did not affect the lag period significantly. After removing microparticles from the samples, the peak thrombin values between patient and control group were no longer significantly different. The difference between microparticle free plasma and platelet poor plasma was significantly higher (p<0.05) in the patient groups without therapy (304±39nM) and in patients on Aspirin therapy (257±23nM) as compared to the normal controls(182.6±10.4nM). These data indicate that thrombin generation is significantly increased in patients with previous myocardial infarction and that this increased thrombin generation is likely due to microparticles contained in these samples. A9 Conclusions. The extended follow-up of the PROLONG study confirms the persistent higher risk of recurrence and the benefit of VKA prolongation in patients with an abnormal D-d at one month after VKAs withdrawal for a first episode of VTE. The optimal duration of anticoagulation in subjects with normal D-d at one month after VKA withdrawal is not clearly established.
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ROLE OF MICROPARTICLES IN THROMBIN GENERATION IN PATIENTS AT RISK FOR ATHEROTHROMBOSIS
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TISSUE FACTOR EXPRESSION IN CIRCULATED PERIPHERAL BLOOD MONOCYTES DURING PROCESS OF ATHEROSCLEROSIS
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PROPHYLAXIS OF THROMBOEMBOLIC COMPLICATIONS IN PREGNANT WOMEN WITH THROMBOPHILIA
A. Makatsariya, S. Akinshina, V. Bitsadze, S. Baimuradova, I. Khamani
Department of obstetrics and gynecology, I. M. Sechenov Moscow Medical Academy, Moscow, Russia
Background: Despite intensive research, thromboembolism still accounts for significant maternal mortality. Aim: To determine thrombophilia in patients with thromboembolism during pregnancy and to evaluate the efficiency of antithrombotic prophylaxis in patients with thrombophilia for prevention of recurrent thromboembolism. Material and methods: Group I: n=37 (28,7±4,2 years), subgroup I (n=20) women with history of thromboembolism associated with pregnancy, subgroup (n=17) women with thromboembolism during current pregnancy, group II (control) -healthy pregnant women (n=35) were screened for genetic thrombophilia and antiphospholipid antibodies (APA). Subgroup I received prophylaxis in preconception period and during pregnancy: low molecular weight heparin (LMWH), omega-3-acides, vitamins of B group, folic acid (up to 4 mg/day), aspirin (80 mg/day). Results: In the subgroup I 40% had familial history of venous thromboembolism, and 60% had personal history of pregnancy complications (fetal loss syndrome, preeclampsia, placental abruption) (p<0,05 vs. control).
In the group I thrombophilia was detected in 100% (4-6 mutations concomitantly including homozygous forms): MTHFR C677T (40,5%), FV Leiden (27%), prothrombin G20210A (18,9%), multigenic fibrinolytic defects (84%); APA (56,7%). In the control group were detected APA (8,6%) and genetic thrombophilia without homozygous forms (20%) (p<0,05). In subgroup I anyone had recurrent thromboembolism, 12% had pregnancy complication (mild preeclampsia) (p<0,05 vs. subgroup II). Conclusions: Thrombophilia might be the essential pathogenetic mechanism of thromboembolism associated with pregnancy. LMWH was effective in 100% cases for prevention of recurrent thromboembolism and obstetric complications.Women with personal or family history of thromboembolism or with history of obstetric complications should be screened for thrombophilia. Varese, Italy, 6 Hospital of Piacenza, Italy, 7 Hospital of Treviso, Italy, 8 Hospital of Venezia, Italy, 9 Hospital of Castelfranco Veneto, Italy, 10 Hospital of Rovigo, Italy, 11 Hospital of Parma, Italy, 12 University of Perugia, Italy
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THE NATURAL HISTORY OF D-DIMER AFTER ANTICOAGULATION SUSPENSION FOR A FIRST EPISODE OF IDIOPATHIC VENOUS
University of
Background. The optimal duration of oral anticoagulant therapy in patients with deep-vein thrombosis of the lower extremities remains uncertain. Methods. The AESOPUS study was a multicenter, randomized clinical trial in consecutive patients with acute proximal deep-vein thrombosis (DVT) who had completed an uneventful 3-month period of anticoagulation. Patients were randomized to a fixed duration of anticoagulation (no further anticoagulation for secondary DVT, an extra 3-month for idiopathic DVT) or to a flexible duration of ultrasound-guided anticoagulation (no further anticoagulation in patients with recanalized veins, continuation of anticoagulation in all other patients up to a maximum of 9 months for secondary DVT and 21 months for idiopathic DVT). The main efficacy outcome was objectively confirmed recurrent venous thromboembolism (VTE) from randomization up to completion of 33 months of follow-up. Results. Recurrent VTE developed in 46 (17.2%) of the 267 patients allocated to the fixed anticoagulant duration, and in 32 (11.8%) of the 271 patients randomized to the flexible duration, for an adjusted hazard ratio of 0.62 (95% CI, 0.39 to 0.97). Major bleeding occurred in 2 (0.7%) patients in the fixed duration group, and 4 (1.5%) in the flexible duration group. In total, 14 thromboembolic events were prevented for 101 years of extra treatment, requiring 82 additional ultrasounds and 2 additional major bleeds. In patients with idiopathic DVT, 13 thromboembolic events were prevented for 65 years of extra treatment, 39 additional ultrasounds and no additional major bleeds. In patients with secondary DVT, only 1 thromboembolic event was prevented for 36 years of extra treatment, 43 additional ultrasounds, and 2 additional major bleeds. Discussion. Tailoring the duration of anticoagulation based on ultrasound findings reduces the rate of recurrent VTE. Limiting this strategy to patients with idiopathic thrombosis will provide the best risk-benefit trade-off and will be the most cost-effective.
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PERCUTANEOUS TREATMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN THE CARDIOLOGY CATHETERIZATION LABORATORY -TECHNIQUE AND RESULTS
G. Mazhdrakov, V. Velchev, N. Rifai, B. Finkov
Dpt. of Cardiology St. Anna Hospital, Sofia, Bulgaria
Main determinants of the outcome in massive and submassive pulmonary embolism are the hemodynamic status and right ventricular dysfunction. Surgical intervention is burdened by significant morbidity and mortality. Intravenous fibrinolysis caries the inherent risk of hemorrhagic complications. Percutaneous techniques were recently simplified and introduced in the field of interventional cardiology. Observational study after percutaneous treatment of massive and submassive PTE in the settings of cathlab. Twelve consecutive patients with acute massive or submassive pulmonary embolism defined as systolic blood pressure below 100mmHg and/or RV dysfunction proven by Echo were treated by trombfragmentation and trombaspiration using conventional angioplasty catheters, followed by local application of half dose fibrinolytic. Hemodynamic data and angiographic Miller score were collected. All patients were followed by Echo and clinical examination. In the end of the procedure we've found an average decrease of heart rate from 111 to 91 bpm, systolic pressure in PA dropped from average 64 to average 50 mmHg, systolic BP raised from average 91 up to 105 mmHg, oxygen saturation raised from 90 to 94%. All of the patient survived with average hospital stay of 5.4 days and no thirty day and 6 months mortality and with good functional capacity. Percutaneous treatment of patient suffering massive and submassive pulmonary trombembolism by thrombfragmentation, aspiration and lisys is feasible. Immediate and late results compares favorably to other treatment modalities. 
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VALUE OF
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Background and aims:
Amputation is the only current option for relief of rest pain or gangrena in patients with severe peripheral arterial disease (SPAD). Up to now, no effective blood-flow enhancement therapies are available. Autologous bone marrow-derived stem cell transplantation (ABMSCT) is an arising therapy modality with an option of building new blood vessels through endothelial stem and/or progenitor cells. Methods: Seven patients with severe peripheral arterial disorder (5 with Buerger's disease and 2 with arteriosclerosis obliterans) were treated by ABMSCT. CD34+, CD133+ and CD45+/-cell number and ratio were determined. CD34+ cells were isolated by magnetic separation and collected into a 10 ml sample. The cell suspension was administered by local intramuscular injection. The follow-up (before: 6-, 12-and 18 months after the ABMSCT) based on clinical (rest pain, walking distance without pain, changes of non-healing ischaemic ulcers, ankle-brachial index) and laboratory (angiography, Color-and Laser-Doppler scan, measurement of TcO 2 P) parameters were documented. Results: Improvement of pain and walking distance was observed in all seven cases. In five cases the non-healing ischaemic ulcers disappeared, in one case became smaller and thinner, and in one case no change was realized. Improvement was observed only on the treated side, the state of contralateral limb remained unchanged or worsened. ASA reduces secondary vascular events, but still 20 % of the patients experience events despite ongoing ASA therapy. To assess influence of risk factors, platelet function and inflammatory response as underlying reason we examined 100 patients with newly diagnosed coronary heart disease who received half either 50 mg or 100 mg ASA daily respectively. Laboratory chemistry, risk factors, platelet function (ADP-, collagen-and epinephrineinduced aggregation, ß-thromboglobulin, thromboxane B 2 ) and inflammatory parameters (CRP, interleukin 6, adhesion molecules [ICAM, VCAM, Eselectin], blood sedimentation rate, fibrinogen) were assessed at 1, 3, 6 and 12 months and thereafter annually for a 10 years follow-up. Compliance was assessed by interview, pill counting, salicylate-and TXB 2 -measurement. (Non) vascular events in both groups were equally frequent all over the observation period. Lethal and non-lethal events were predicted by increased inflammatory response (CRP 3, 51 vs. 0, 85; VCAM 689, 3 vs. 608, 8, among others) , but not by any of the platelet function tests. The platelet function was more activated in cigarette smokers and in hyperlipidemia, the quintile distribution, however, did not change significantly over 10 years. Patients with a more activated platelet population were not more prone to develop events. There was no difference between the 50 and 100 mg dose of ASA. We found no signs for the so-called ASA-resistance. Enhanced inflammatory activity before the event (as compared to starting-and prevalue) was the most striking finding in all the patients. Deep venous thrombosis (DVT) is a multifactorial disease and in about 30% of patients no risk factor can be identified. Association of inflammation and hemostasis is closely related. Considering leukocyte migration as one of the main events which characterize the inflammatory process, expression of inflammatory mediators in mononuclear cells in patients with previous DVT was analyzed. cDNA microarrays technology (CodeLink Bioarrays) was chosen to study the profile of genetic expression in inflammatory mediators in DVT spontaneous patients and healthy siblings. These microarrays were hybridized with synthesized probes from samples collected from 2 patients (2 males, mean age 40) 6 months after DVT occurrence and their siblings (1 male, 1 female; mean age 43.5) (pools of RNA). Preliminary analysis showed that 2% of approximately 55,000 transcripts contained in the array had significant differences in expression in DVT spontaneous patients relative to their siblings. The induced genes are particular to immune and inflammatory response, motility and cell adhesion, i.e. HLA-DQA1, TNFAIP6, IL4R; repressed genes are related to defense response, signal transduction, i.e. CLEC2, NFKBIA, TNFRSF21. Earlier results indicated that induced genes are associated with the mobilization of cells and response starting compounds which induce inflammation. The repressed genes detected, i.e. related to apoptosis inhibition, inappropriate immune cell development, suggest the organism's deficiency to reestablish homeostasis. Evaluation of the role played by the regulation of these genes in spontaneous venous thrombosis compared with healthy individuals with similar genotypes could be important to better understand the physiopathological mechanisms involved.
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ANALYSIS OF THE GENETIC EXPRESSION OF INFLAMMATORY
A12
Background: Metaanalysis of reported data on Factor XIII A subunit (FXIII-A) Val34Leu polymorphism have demonstrated that the presence of Leu34 allele provides protection against coronary artery disease. A few reports has also been published concerning the effect of FXIII-A Val34Leu polymorphism on the risk of ischemic stroke, however the results were inconclusive. In these studies stroke survivors and non-survivors were not analyzed separately. Patients and methods: DNA samples were isolated from 508 patients (male/female: 168/170) who survived ischemic stroke and from tissue sections of 456 patients (male/female: 223/233) died of ischemic stroke. FXIII-A Val34Leu genotypes were determined using melting point analysis and fluorescence resonance transfer detection. A population control group was used for comparison. Results: Leu34 carriership did not show significant association with lethal stroke. However, when heterozygotes and homozygotes for the Leu34 allele were investigated separately an interesting opposing effect was observed. Val/Leu heterozygosity represented a moderate, but significant protective effect (OR: 0.720, 95%CI: 0.546-0.950). In contrast, the Leu/Leu genotype indicated a 3-fold risk (OR: 3.194, ) of stroke with lethal outcome. In females with Leu/Leu genotype the risk was somewhat higher than in males the ORs were 3.756 and 2.791, respectively. Neither Val/Leu nor Leu/Leu genotype influenced the frequency of non-lethal stroke to any significant extent. Conclusions: FXIII-A Val34Leu polymorphism influenced only the severity (lethal outcome) of ischemic stroke. The Val/Leu and Leu/Leu genotypes exerted opposite effects. Further investigations are required to explore the pathobiochemical background of differences. A13 Introduction: Bleeding is the most common side effect of Warfarin therapy. The human CYP2C's are enzymes that metabolizes Warfarin. Two polymorphism are reported in patients who require small dose of Warfarin for maintenance. Such patients show more serious bleeding, and are difficult to control. These polymorphisms show significant racial and geographic differences. Their prevalence in the Saudi and other Arab population is not known. Aim: ñ To define the prevalence of the CYP2C9 polymorphism in the normal Saudi population and patients who required less than 2 mg Warfarin as maintenance dose. ñ To test the hypothesis that these polymorphism being associated with excessive bleeding may protect against venous thrombosis. Patients and Method: DNA was extracted from venous blood of consenting individuals using established method. Polymerase chain reaction (PCR) was used to detect the CYP2C9 * 2 and CYP2C9 * 3 polymorphism. Results: We tested 670 normal controls, 150 patients with confirmed DVT and 40 who required 2mg or less of Warfarin. Table 1 shows the results. 
Conclusion:
ñ CYP2C9 polymorphism prevalence in patients with DVT is similar to the normal population, and thus show no relation to venous thrombosis. ñ CYP2C9 polymorphism is found significantly more in Saudi patients who require low Warfarin maintenance dose.
